1.
Inflamm Bowel Dis
; 7(1): 34-7, 2001 Feb.
Article
in English
| MEDLINE
| ID: mdl-11233658
ABSTRACT
Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulizing Crohn's disease (CD), but can be associated with the development of severe allergic reactions during retreatment, precluding further use of the medication. We present two CD patients (one adult and one child) with a history of anaphylactic/anaphylactoid reactions to retreatment with infliximab who subsequently underwent successful desensitization and therapeutic infusion using parenteral dose escalation in an intensive care unit setting.
Subject(s)
Anaphylaxis/etiology , Antibodies, Monoclonal/therapeutic use , Crohn Disease/drug therapy , Crohn Disease/immunology , Desensitization, Immunologic/methods , Adult , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Child , Female , Gastrointestinal Agents , Humans , Infliximab , Intensive Care Units , Male
2.
Ann Allergy Asthma Immunol
; 85(6 Pt 1): 450-6, 2000 Dec.
Article
in English
| MEDLINE
| ID: mdl-11190255
Subject(s)
Exanthema/etiology , Pruritus/complications , Adult , Diagnosis, Differential , Exanthema/diagnosis , Female , Humans , Pruritus/diagnosis
3.
Circulation
; 34(6): 1034-43, 1966 Dec.
Article
in English
| MEDLINE
| ID: mdl-5928549